United Health Products, Inc. (UEEC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
United Health Products, Inc. (UEEC) trades at $0.06 with AI Score 42/100 (Grade C). United Health Products, Inc. focuses on developing, manufacturing, and marketing hemostatic gauze products. Market cap: $15.22M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for UEEC: UEEC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UEEC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
UEEC: the 1 perspectives are evenly split.
How is this calculated? →United Health Products, Inc. (UEEC) Healthcare & Pipeline Overview
United Health Products, Inc. specializes in hemostatic gauze products, primarily HemoStyp, targeting diverse healthcare sectors including hospitals, clinics, military, and first responders. The company operates in the competitive wound care market, focusing on bleeding control and wound management solutions within the United States.
What Is the Investment Thesis for UEEC?
United Health Products, Inc. presents a focused investment opportunity within the hemostatic gauze market. The company's reliance on a single product, HemoStyp, creates both potential and risk. Growth hinges on expanding market penetration within existing channels and securing new distribution agreements. Key value drivers include increasing sales volume of HemoStyp, achieving regulatory approvals for expanded indications, and strategic partnerships to broaden market reach. The company's negative P/E ratio of -5.07 reflects current challenges in achieving profitability. Investors should monitor revenue growth, gross margins, and cash flow closely to assess the company's financial health and long-term viability. Upcoming catalysts include potential new distribution agreements and regulatory approvals.
Based on FMP financials and quantitative analysis
UEEC Key Highlights
- Market capitalization of $15.22M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -5.07 suggests the company is currently not profitable, requiring close monitoring of financial performance.
- Beta of -0.88 indicates the stock is less volatile than the market, which may appeal to risk-averse investors.
- Focus on HemoStyp hemostatic gauze provides a specialized product offering within the wound care market.
- Distribution across diverse healthcare settings, including hospitals, clinics, and military facilities, offers multiple revenue streams.
Who Are UEEC's Competitors?
UEEC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.87 | -5.97% | $39.39M | 45 |
| CRVW CareView Communications, Inc. | $0.05 | -8.31% | $30.65M | 54 |
| GTHP Guided Therapeutics, Inc. | $0.28 | +14.29% | $21.48M | 44 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UEEC's Key Strengths?
- Specialized product offering (HemoStyp).
- Distribution network across diverse healthcare settings.
- Focus on bleeding control and wound care.
- Established presence in the US market.
What Are UEEC's Weaknesses?
- Limited product portfolio (reliance on HemoStyp).
- Small company size and limited resources.
- Negative P/E ratio indicates lack of profitability.
- Dependence on US market.
What Could Drive UEEC Stock Higher?
- Potential new distribution agreements to expand market reach.
- Regulatory approvals for expanded indications of HemoStyp.
- Increasing sales volume of HemoStyp in existing markets.
- Strategic partnerships to broaden market reach.
- Development of new hemostatic products.
What Are the Key Risks for UEEC?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the wound care market.
- Stringent regulatory requirements.
- Product liability claims.
- Economic downturn affecting healthcare spending.
- Limited product portfolio (reliance on HemoStyp).
What Are the Growth Opportunities for UEEC?
- Expansion into New Geographic Markets: United Health Products can explore opportunities to expand its market presence beyond the United States. International markets, particularly in regions with growing healthcare expenditures and unmet needs for advanced wound care, represent a significant growth avenue. This expansion would require navigating regulatory hurdles and establishing distribution networks in new territories. The global wound care market is projected to reach $22 billion by 2028, offering substantial potential for revenue growth.
- Development of New Hemostatic Products: Investing in research and development to expand its product portfolio beyond HemoStyp can drive future growth. Developing new hemostatic agents with enhanced efficacy, ease of use, or specific applications could attract new customers and increase market share. This includes exploring advanced materials and formulations to improve wound healing outcomes. The timeline for new product development typically ranges from 2-5 years, depending on regulatory requirements and clinical trials.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with larger medical device companies or acquiring complementary businesses can accelerate growth. Partnerships can provide access to established distribution networks, marketing resources, and technological expertise. Acquisitions can expand the company's product portfolio and market reach. The medical device industry is characterized by frequent M&A activity, presenting opportunities for United Health Products to enhance its competitive position.
- Increased Penetration in Military and First Responder Markets: Focusing on expanding sales to military medical care providers, EMS, fire departments, and other first responders can provide a stable revenue stream. These markets require reliable and effective hemostatic products for trauma care. Securing contracts with government agencies and emergency medical services can provide long-term revenue visibility. The market for hemostatic agents in military and first responder settings is estimated at $500 million annually.
- Focus on Veterinary Applications: Expanding the use of HemoStyp in veterinary hospitals and clinics represents a niche growth opportunity. Veterinary medicine increasingly utilizes advanced wound care products, creating demand for hemostatic agents. This market segment offers less stringent regulatory requirements compared to human healthcare, potentially accelerating product adoption. The global veterinary wound care market is projected to reach $1.5 billion by 2027, presenting a viable growth avenue for United Health Products.
What Opportunities Does UEEC Have?
- Expansion into new geographic markets.
- Development of new hemostatic products.
- Strategic partnerships and acquisitions.
- Increased penetration in military and first responder markets.
What Threats Does UEEC Face?
- Intense competition in the wound care market.
- Stringent regulatory requirements.
- Potential product liability claims.
- Economic downturn affecting healthcare spending.
What Are UEEC's Competitive Advantages?
- Specialized product offering in hemostatic gauze.
- Established presence in the wound care market.
- Distribution network across diverse healthcare settings.
- Proprietary formulation of HemoStyp.
What Does UEEC Do?
United Health Products, Inc., established in 1997 and rebranded in 2010 from United EcoEnergy Corp., is a company focused on the development, manufacture, and marketing of hemostatic gauze products. Headquartered in Henderson, Nevada, the company's flagship product is HemoStyp, a hemostatic gauze designed to control bleeding and absorb exudate from superficial wounds. HemoStyp is distributed across a range of healthcare settings, including hospitals, surgery centers, clinics, physicians' offices, military medical facilities, hemodialysis centers, assisted living and nursing homes, and veterinary hospitals. The product is also utilized by EMS, fire departments, other first responders, and dental, oral, and maxillofacial surgery offices. The company aims to provide effective wound care solutions to various medical professionals and organizations, addressing the critical need for bleeding control in diverse clinical scenarios. With a small team of 7 employees, United Health Products operates primarily within the United States.
What Products and Services Does UEEC Offer?
- Develops hemostatic gauze products.
- Manufactures HemoStyp hemostatic gauze.
- Markets HemoStyp to healthcare providers.
- Provides solutions for bleeding control.
- Offers products for wound exudate absorption.
- Serves hospitals and surgery centers.
- Caters to military medical care providers.
- Supplies EMS and first responders.
How Does UEEC Make Money?
- Develops and manufactures hemostatic gauze products.
- Markets and sells HemoStyp directly to healthcare providers and distributors.
- Generates revenue through product sales.
- Focuses on bleeding control and wound care solutions.
What Industry Does UEEC Operate In?
United Health Products, Inc. operates in the medical instruments and supplies industry, a segment within the broader healthcare sector. The industry is characterized by continuous innovation, stringent regulatory requirements, and intense competition. The wound care market, in particular, is driven by factors such as the aging population, rising incidence of chronic diseases like diabetes, and increasing demand for advanced wound care products. Competitors range from large, established medical device companies to smaller, specialized players. United Health Products focuses on a niche within this market, offering hemostatic gauze products, and must compete on product efficacy, pricing, and distribution channels.
Who Are UEEC's Key Customers?
- Hospitals and surgery centers.
- Clinics and physicians' offices.
- Military medical care providers.
- EMS, fire departments, and other first responders.
- Veterinary hospitals and clinics.
Company Profile
United Health Products, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Mount Laurel, US. The company is led by CEO Brian D. Thom. UEEC has traded publicly since 2007.
F-Score 2/9Financial Health
United Health Products, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 40%Key Financial Metrics
Return on equity for United Health Products, Inc. stands at 39.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -9.5%, the inverse of the P/E and a quick read on earnings relative to price.
UEEC Valuation & Market Position
With a $15.22M market cap, United Health Products, Inc. sits in the micro-cap segment of the market. Relative to its peer group, UEEC's quantitative score of 42/100 is below the peer average of 56/100.
UEEC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized product offering (HemoStyp).
- Distribution network across diverse healthcare settings.
- Focus on bleeding control and wound care.
- Established presence in the US market.
Bear Case
- Limited product portfolio (reliance on HemoStyp).
- Small company size and limited resources.
- Negative P/E ratio indicates lack of profitability.
- Dependence on US market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
UEEC Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
UEEC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UEEC.
Price Targets
Wall Street price target analysis for UEEC.
UEEC MoonshotScore
What does this score mean?
The MoonshotScore rates UEEC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Brian D. Thom
CEO
Brian D. Thom serves as the CEO of United Health Products, Inc. His background includes experience in managing small teams and guiding companies through various stages of development. He is responsible for overseeing the company's strategic direction, product development, and market expansion efforts. His leadership is focused on driving revenue growth and achieving profitability.
Track Record: Under Brian D. Thom's leadership, United Health Products has focused on expanding the distribution of HemoStyp and exploring new market opportunities. Key milestones include securing distribution agreements with healthcare providers and increasing sales volume. His strategic decisions aim to position the company for long-term growth and success in the competitive wound care market.
UEEC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that United Health Products may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in UEEC.
- Low liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- Price volatility can be higher due to limited trading volume.
- The company may not meet the minimum financial standards of higher OTC tiers.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's competitive position in the wound care market.
- Analyze the company's revenue growth and profitability trends.
- Review the company's debt levels and cash flow.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- The company has been in operation since 1997.
- HemoStyp is distributed across diverse healthcare settings.
- The company has a focus on a specific niche market (hemostatic gauze).
- Company has a CEO in place.
- Company has a physical headquarters.
UEEC Healthcare Stock FAQ
What does United Health Products, Inc. do?
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products, primarily HemoStyp, designed to control bleeding and absorb exudate from superficial wounds. The company targets a diverse range of healthcare settings, including hospitals, clinics, military medical facilities, and first responders. Their business model focuses on providing specialized wound care solutions to medical professionals and organizations, addressing the critical need for effective bleeding control in various clinical scenarios. Revenue is generated through the sale of HemoStyp and future product offerings.
What are the main risks for UEEC?
United Health Products, Inc. faces several risks, including intense competition in the wound care market, stringent regulatory requirements, and potential product liability claims. The company's reliance on a single product, HemoStyp, exposes it to product-specific risks and limits its revenue diversification. As an OTC-listed company, UEEC faces risks associated with limited liquidity, disclosure, and regulatory oversight. Economic downturns affecting healthcare spending could also negatively impact the company's financial performance. Investors should carefully assess these risks before investing in UEEC.
What are the key factors to evaluate for UEEC?
United Health Products, Inc. (UEEC) holds an AI score of 42/100 (low). Not financial advice.
How frequently does UEEC data refresh on this page?
UEEC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven UEEC's recent stock price performance?
United Health Products, Inc. (UEEC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product offering (HemoStyp). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UEEC overvalued or undervalued right now?
Valuing United Health Products, Inc. (UEEC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying UEEC?
Before investing in United Health Products, Inc. (UEEC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding UEEC to a portfolio?
Key strength of United Health Products, Inc. (UEEC): Specialized product offering (HemoStyp). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage and financial data available for UEEC due to its OTC listing.
- Information based on publicly available sources and company filings.